| CAS NO: | 496807-11-5 |
| Cas No. | 496807-11-5 |
| 别名 | (Rac)-贝拉前列素钠 |
| Canonical SMILES | CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@@]2([H])C3=CC=CC(CCCC(O[Na])=O)=C3O[C@@]2([H])C[C@H]1O.[Relative stereochemistry] |
| 分子式 | C24H29NaO5 |
| 分子量 | 420.47 |
| 溶解度 | DMSO: 250 mg/mL (594.57 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation[1]. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity[1]. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell-cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions[1]. Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis[1]. Animal Model: 6-8-week-old C57Bl/6J Male Mice[1] [1]. Li S, et al. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels.J Mol Med (Berl). 2019 Jun;97(6):777-791. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |